GHC News Flash: Global Health Roundup 1/9/2017

.
Major Ebola Vaccine Clinical Trial Concludes
The global health community wrapped up an eventful year with the conclusion of a major clinical trial which evaluated the effectiveness of a new Ebola vaccine on 6,000 subjects in Guinea. The one-year trial was led by the WHO, Guinea’s Ministry of Health, Médecins Sans Frontières, and other international partners. Findings from the trial reveal that the new vaccine is up to 100 percent effective. “While these compelling results come too late for those who lost their lives during the West Africa Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenseless,” said Dr. Marie-Paul Kieny, WHO Assistant Director-General for Health Systems and Innovation, and the study’s lead author. Read more.
.

.
Upcoming World Economic Forum Annual Meeting
In 2016, the world marked one year since the adoption of the Sustainable Development Goals (SDGs). Some of the achievements that were made in that year include the signing of a historical climate change agreement, renewing efforts towards gender equality, and advancing the Global Health Security Agenda. At this year’s World Economic Forum, leading voices in business and global development will meet in Davos, Switzerland to discuss ways we can build on this momentum and further our progress in solving global issues. A major highlight at this event will be the launch of the Coalition for Epidemic Preparedness Innovations (CEPI), a new global effort that seeks to stop future epidemics by developing timely vaccines.
.

.
Gates Foundation Invests in New HIV Prevention Device
The Bill and Melinda Gates Foundation recently committed to investing up to 140 million dollars towards the development of a new HIV prevention device. The device, a small implantable drug pump, is being developed by Intarcia Therapeutics, Inc. to facilitate the delivery of antiretroviral medicines over extended periods of time. This will help ensure that patients on HIV treatment do not miss a single dose. While it might take several years to get the device onto the market, the agreement between the Gates Foundation and Intarcia Therapeutics, Inc. is intended to make sure that the intervention is accessible and affordable to low resource populations in the developing world. Read more.
.

.
Call for Applications: Alan Fagil Fellowship
GHC member American Society for Tropical Medicine and Hygiene (ASTMH) has launched a fellowship in honor of the legacy of Alan J. Fagil, a celebrated leader in the global tropical medicine community. The fellowship is targeted towards early-to-mid-career ASTMH members in low- and middle-income countries and will support leadership development in tropical medicine. The recipient will receive funding of up to $50,000 over a period of two years. Deadline for submission is February 1. View the Call for Concept Papers for more details.